The A-List: The Trend-Shaping Series A Financings Of 2014
This article was originally published in Start Up
Executive Summary
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.
You may also be interested in...
2015 Exits: Biotech’s Big Year
Fewer companies went public in 2015 than during the peak year of 2014, but on average 2015’s US IPO crop raised more money and at better valuations. And thanks to a jump in private biotech acquisition volume and valuations, investors enjoyed a tremendous year for biotech exits.
The A-List: The Trend-Shaping Series A Financings Of 2015
Our 12th annual analysis reveals both an expansion of historical patterns of Series A financings and the emergence of a new group of heavily committed, relatively short-term investors.
Series A Deal Volume And Money Up In H1
Biopharma, medtech and diagnostics start-ups raised a whopping 51% more Series A money in the first half of 2015 than during the same period last year, and the number of deals was way up too.